Monday, December 9, 2019
-18 °c
StockWatch247
  • Active Stocks
  • Earnings
  • New Issues – IPOs
  • Stocks To Watch
  • Technology
  • Top Performers
  • Small Cap
No Result
View All Result
  • Active Stocks
  • Earnings
  • New Issues – IPOs
  • Stocks To Watch
  • Technology
  • Top Performers
  • Small Cap
No Result
View All Result
StockWatch247
No Result
View All Result
Home New Issues - IPOs

Outlook Therapeutics (OTLK) Active Pre-Market, Stock Soars and Outperforms Most Recent Nasdaq IPOs

by Stock Watch 247 Team
May 20, 2019
in New Issues - IPOs, Top Performers
3 min read
0
Share on FacebookShare on Twitter

Outlook Therapeutics, Inc. [NASDAQ: OTLK] premarket update today, on the first day of trading this week, shows that the stock is not only in the green but also still bullish and very active premarket. In the premarket update published by StockWatch247 last week on OTLK, the stock was easily one of the Top performers on the market. As previously mentioned, OTLK began the journey of breaking barriers following excitement associated by Oppenheimer analyst Leland Gershell prediction that gave the stock a $12 target in the short-term. OTLK has been on a technical chart breakout the past several days and has outperformed most IPOs.

The stock rallied incredibly on Friday last week adding more than 37% (Nasdaq summary quote) to its value. Moreover, OTLK broke above the $1.00 market in turn opening the door for gains that not only touched $2.00 but also recorded highs around $2.72. According to the real-time quote by Nasdaq, Outlook Therapeutics, Inc. closed the market last Friday up 44.44% after a relative change of +0.68.

RELATED POSTS

Synthorx Inc (NASDAQ: THOR) Accepts Buyout Deal From Sanofi at a 172% Premium

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Phase 3 Studies for Lupus Nephritis a Success

Besides, it had an NLS volume of 33,568,085. On the very day, the stock ascended to intraday highs of $2.72 compared to its 52-week high at $10.96. Significantly, closed above its 52-week low ($0.85) at $1.63. Previously, OTLK had closed the session at $1.53 in addition to having a share volume of 76,650,653 and a 50-day average daily volume of 1,641,629. The rapidly growing biotechnology company currently has a market capitalization of $24,701,250.

The ballistic move last Friday has been directly linked to high trading volume catalyzed by fresh interest in the stock. Currently, Outlook Therapeutics is working on a new formula that will see it device treatment for wet age-related macular degeneration.

Consequently, the gains come after the company released business highlights as well as the financial report for the Q2 for the fiscal period ending March 31, 2019. In the highlights Outlook Therapeutics has the FDA accepted while the activation for the IND ONS-5010 application already started. It has commenced the ONS-5010-002 Phase 3 testing. In addition, its IPO that raised $28.4 million had been completed successfully. Lawrence A. Kenyon, President, the CEO and CFO said in regards to the highlights:

“We are pleased with the progress being made in both of our Phase 3 clinical trials for ONS-5010 thus far in 2019, which includes the FDA’s acceptance of our IND for ONS-5010 and the initiation of our second Phase 3 trial.  The two studies remain on track with our plan to submit ONS-5010 for regulatory approval in multiple markets in 2020.”

He added:

“The financing we secured in the equity offering announced in April has provided us with the capital needed to complete enrollment in our two Phase 3 clinical trials. This was an important step in our strategy and to maintain the positive momentum behind our clinical development program for ONS-5010.”

[NASDAQ: OTLK] Technical Picture

Looking at the 15-minutes chart, we see an asset that is still in a bullish momentum pre-market trading on Monday May 20. The stock is trading above the 61.8% Fib level support taken between the last swing high at $2.72 and a low of $0.89. The RSI is in an upward is pointing upwards while the MACD is still in the positive region in spite of the change of direction towards the mean level (0.0). Moreover, the stock is still enjoying support from the 200 SMA 15’ in addition to the ascending trendline support.

Tags: Day TradingNASDAQOTLKOutlook TherapeuticsPre Market TradingStock ChartsStock TradingSwingTrading
ShareTweetShare

Related Posts

Synthorx Inc (NASDAQ: THOR) Accepts Buyout Deal From Sanofi at a 172% Premium
Stocks To Watch

Synthorx Inc (NASDAQ: THOR) Accepts Buyout Deal From Sanofi at a 172% Premium

by Stock Watch 247 Team
8 hours ago

Synthorx Inc (NASDAQ: THOR) has been on an uptrend since November. At the moment, the stock is trending on news...

Read more
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Phase 3 Studies for Lupus Nephritis a Success
Stocks To Watch

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Phase 3 Studies for Lupus Nephritis a Success

by Stock Watch 247 Team
4 days ago

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is surging in pre-market trading. At the moment, it is up by over 100% to...

Read more
Audentes Therapeutics Inc (NASDAQ: BOLD) Gaps Up After a Premium-Priced Buyout
Top Performers

Audentes Therapeutics Inc (NASDAQ: BOLD) Gaps Up After a Premium-Priced Buyout

by Stock Watch 247 Team
5 days ago

Audentes Therapeutics Inc (NASDAQ: BOLD) was one of the biggest gainers in Tuesday’s trading session. The stock rallied to close...

Read more
Proteostasis Therapeutics (NASDAQ: PTI) Gains As It Completes Enrollment For Treatment Study
Active Stocks

Proteostasis Therapeutics (NASDAQ: PTI) Gains As It Completes Enrollment For Treatment Study

by Stock Watch 247 Team
2 weeks ago

Proteostasis Therapeutics Inc (NASDAQ: PTI) was one of the biggest gainers in Tuesday’s trading session. It gained by over 26.98% to...

Read more
Active Stocks: Karuna Therapeutics (KRTX) Rallies on Trials for Schizophrenia Treatment
Active Stocks

Active Stocks: Karuna Therapeutics (KRTX) Rallies on Trials for Schizophrenia Treatment

by Stock Watch 247 Team
3 weeks ago

Active Stocks: Karuna Therapeutics Inc opened the trading week with huge gains. The stock shot up by 442.99%...

Read more
Next Post
NASDAQ: MIST

Stocks To Watch: Milestone Pharmaceuticals (MIST) IPO Continues Technical Uptrend

NYSE: S

Sprint Corporation (S) Up as FCC Chairman Supports a Merger with T-Mobile

Please login to join discussion

MOST VIEWED

  • NASDAQ: FCEL

    FuelCell Energy (FCEL) Gains by Over 10% in Pre-market Trading

    0 shares
    Share 0 Tweet 0
  • JUMIA TECHNOLOGIES AG (JMIA) After IPO Surge Ends as The Stock Sees a 13% Slump

    0 shares
    Share 0 Tweet 0
  • Amazon (AMZN) – Amazon likely to stay bullish this quarter: The fundamentals support it

    1 shares
    Share 1 Tweet 0
  • Tufin Software Technologies (TUFN) Continues to Show Strength in the Market

    2 shares
    Share 2 Tweet 0
  • Jumia Technologies AG (JMIA) Stock: Likely the Undiscovered Africa’s New ‘Gold’

    0 shares
    Share 0 Tweet 0

Stock Watch 247

Stock Watch 247 is a leading provider and publisher of stock market news, initial public offering (IPO) news, new stock listings and stocks to watch, commentary, business news, financial news and content on the USA & World Markets. Stock Watch 247 is for information only and not investment advice. Please make sure to read our Disclaimer and Privacy Policy. We may be buying or selling any stock discussed at any time.

Categories

  • Active Stocks
  • Earnings
  • New Issues – IPOs
  • Stocks To Watch
  • Technology
  • Top Performers
  • Small Cap

Grocery Outlet (GO) Goes Public and Closes below Where it Opened for Trading

Active Stocks: Precipio (PRPO) Breaks Out On Positive IV-Cell News – Will It Trade Higher?

Eltek (ELTK) Goes Parabolic on Positive Q1 Results – Turnaround Strategy Starts to Bear Fruit

NASDAQ: ROKU Surges After Guggenheim Raises Target to $119 – Fundamentals Getting Stronger Too

Bristol-Myers Squibb (BMY) Sustains 12.6% Bull Run And Outperforms The Medical Sector

Symantec Corporation (SYMC) – Is the Worst Over After Monday’s Sell off?

SUBSCRIBE TO OUR FREE VIP NEWSLETTER: Get Trade Reports, Ideas, Breaking News and more!

By clicking "Subscribe" I agree to the Privacy Policy & Disclaimer presented on this site.

  • About Us
  • Our Team
  • Privacy Policy
  • Disclaimer
  • Contact Us

© 2019 StockWatch247 - Copyright © All Rights Reserved.

No Result
View All Result
  • Active Stocks
  • Earnings
  • New Issues – IPOs
  • Stocks To Watch
  • Technology
  • Top Performers
  • Small Cap

© 2019 StockWatch247 - Copyright © All Rights Reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In